Figure 1: Total cost of antimalarials and RDTs: comparing Clinical and Definitive diagnosis

Note: The positive figures are incremental (additional) costs, while the negative figures are cost savings.

Figure 2: Incremental costs (or cost savings) associated with use of RDTs when malaria is confirmed in varying proportions of patients for two ACTs (AS+SP and artemether-lumefantrine); excluding ‘other recurrent costs’.

Note: The positive figures are incremental (additional) costs, while the negative figures are cost savings.